Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market

NetworkNewsWire Editorial Coverage

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Artificial intelligence (AI) continues to transform healthcare innovation, with medical imaging emerging as one of its most promising frontiers. In breast cancer detection, where early identification often determines patient outcomes, AI-powered imaging technologies are pushing beyond the technical constraints of traditional mammography, tomosynthesis, and MRI. Globally, breast cancer remains the most frequently diagnosed cancer among women. The World Health Organization (WHO) reported that more than 2.3 million women were diagnosed, with approximately 670,000 losing their lives to the disease in 2022. In the United States, the American Cancer Society (ACS) estimates that 316,950 new invasive breast cancer cases will be identified this year alone. This urgent demand for faster, more accurate diagnostic tools is driving a surge of innovation across the imaging sector. Within this fast-evolving field, Izotropic Corporation (CSE:IZO) (OTCQB:IZOZF) (profile) is distinguishing itself with the IzoView Breast CT Imaging System, a purpose-built 3D imaging solution engineered to enhance cancer detection accuracy, particularly in women with dense breast tissue. IzoView aligns with leading innovators such as NVIDIA Corp. (NASDAQ:NVDA), Butterfly Network Inc. (NYSE:BFLY), Lantheus Holdings Inc. (NASDAQ:LNTH), and RadNet Inc. (NASDAQ:RDNT), all of which are driving the integration of artificial intelligence into the future of medical imaging.

• Izotropic continues to progress toward commercializing IzoView, its dedicated breast CT imaging system designed to improve detection in women with dense breast tissue.
• The company highlights scalability and flexibility as central to the IzoView platform's commercial appeal.
• Izotropic stands apart by developing and protecting a proprietary AI image reconstruction algorithm, refined over more than 15 years using exclusive breast CT data and maintained as a trade secret.
• Izotropic's long-term strategy for IzoView extends well beyond the imaging device itself — it aims to establish the platform as an integrated component of the AI-driven diagnostic ecosystem.
• The market landscape surrounding Izotropic is both substantial and accelerating.

Click here to view the custom infographic of the Izotropic Corporation editorial.

The fusion of artificial intelligence (AI) and three-dimensional (3D) medical imaging is redefining diagnostic accuracy and efficiency. While traditional mammography has saved countless lives, its two-dimensional imaging format and need for physical compression limit visibility of internal structures, particularly in complex tissue.

Dense breast tissue — found in over half of all women — remains one of the greatest challenges in cancer screening. Its fibroglandular composition can obscure or imitate malignancies, leading to missed or delayed diagnoses. Studies have shown that mammography's sensitivity drops significantly in dense breasts, as overlapping tissue often conceals abnormalities that would otherwise be detectable.

AI-powered imaging analysis now offers an innovative path forward. Through advanced algorithms that enhance contrast, suppress noise, and identify subtle image patterns, AI can reveal clinical details that elude even expert radiologists. In computed tomography (CT), AI-based image reconstruction has demonstrated the ability to improve clarity while maintaining or lowering radiation exposure. In breast imaging, deep learning systems are increasingly matching or surpassing radiologists in detecting, segmenting and classifying lesions, especially in dense or early-stage cases.

The combination of AI with advanced volumetric imaging platforms, such as MRI and dedicated breast CT, reflects a broader shift toward intelligent, data-driven diagnostics. These systems can simultaneously generate and interpret 3D information, supporting faster, more consistent, and more precise decision-making.

Positioned at the center of this evolution, Izotropic Corporation has developed the IzoView Breast CT Imaging System, a high-resolution volumetric imaging platform engineered to bridge the gap between digital breast tomosynthesis and MRI. IzoView integrates proprietary AI reconstruction technology derived from more than a decade of specialized breast CT data. This trade-secret algorithm, along with its potential integration with future computer-aided diagnosis (CADx) applications, underscores Izotropic's role in shaping the next generation of AI-enhanced breast cancer detection.

Izotropic Corporation continues to progress toward commercializing IzoView, its dedicated breast CT imaging system designed specifically to improve detection in women with dense breast tissue, an underserved and clinically significant segment of the population. Roughly half of women in the United States have dense breasts, a condition that can obscure lesions and increase the likelihood of missed cancers on traditional mammograms. IzoView is engineered to address this challenge by delivering 3D volumetric imaging with enhanced contrast resolution—without the need for breast compression.

In its regulatory and commercialization materials, Izotropic highlights IzoView's suitability for dense breast imaging, citing clinical literature and prototype data that demonstrate the advantages of breast CT in such cases. Because standard mammography offers reduced diagnostic benefit for women with dense tissue, both regulatory authorities and patient advocacy groups have increasingly called for supplemental screening options. This growing demand expands the market potential for advanced imaging technologies like IzoView.

Investor presentations further indicate that Izotropic plans for IzoView to serve both screening and diagnostic functions. The system is expected to enter the market as a complementary tool to digital breast tomosynthesis, providing MRI-comparable imaging, with the long-term goal of achieving regulatory clearance to replace certain existing modalities. Designed to integrate into radiology departments, breast centers, and hospital workflows, IzoView aims to deliver a cost-effective and scalable platform for improved imaging in women with dense breast tissue.

By concentrating its commercialization strategy on this specialized need, Izotropic seeks to align IzoView's rollout with evolving clinical guidelines, insurance reimbursement trends, and the growing demand for precision imaging—an approach that positions the company strategically within the medtech landscape.

Izotropic Corporation highlights scalability and flexibility as central to the IzoView platform's commercial appeal. According to company disclosures, IzoView is designed with a target sale price of around $500,000, a fraction of the cost of many traditional breast CT systems that can exceed $1.5 million. This price point could make advanced 3D breast imaging accessible to a much broader range of imaging centers, particularly in outpatient and distributed healthcare environments.

The company's development roadmap outlines 14 Indications for Use (IFUs), supporting a software-driven growth model that enables recurring revenue through future feature releases, new imaging applications, and enhanced clinical capabilities spanning screening, diagnosis, treatment planning, and personalized medicine. This modular approach allows the hardware foundation to remain constant while software updates expand the system's utility over time.

IzoView's engineering also facilitates installation in high-volume or decentralized care settings, thanks to its self-shielded design and efficient workflow that eliminates the need for dedicated radiation-shielded rooms. These attributes significantly lower infrastructure barriers for smaller facilities or regional hospitals, especially in markets where the cost of MRI suites and specialized shielding is prohibitive.

By integrating competitive pricing, upgradeable architecture and multi-application versatility, Izotropic positions IzoView as more than a single-use imaging device; it's a scalable diagnostic platform designed to evolve with clinical needs and technological advances.

In the rapidly evolving field of AI-driven medical imaging, many technologies trend toward commoditization; as open-source algorithms proliferate and competing vendors refine similar models, true differentiation becomes increasingly difficult. Izotropic Corporation stands apart by developing and protecting a proprietary AI image reconstruction algorithm, refined over more than 15 years using exclusive breast CT data and maintained as a trade secret. This extensive, specialized dataset represents a strategic asset that can provide Izotropic with a lasting competitive edge in an otherwise crowded market.

The company's algorithm produces denoised, high-quality CT images while preserving low radiation doses comparable to standard two-view mammography, a vital consideration in breast imaging, where minimizing radiation exposure is a clinical priority. This balance between image clarity and safety strengthens the diagnostic foundation for downstream computer-aided detection and diagnosis (CADx) tools, as improved reconstruction directly enhances the accuracy of AI-based interpretation systems.

By safeguarding its reconstruction model as a trade secret rather than a shared or licensed framework, Izotropic limits the risk of replication from competitors that depend on publicly available AI architectures. This approach effectively establishes a technological moat, protecting the company's intellectual advantage. As validation studies progress and future diagnostic AI modules are layered onto this foundation, Izotropic's integrated imaging platform could deepen its competitive positioning even further.

Izotropic Corporation's long-term strategy for IzoView extends well beyond the imaging device itself — it aims to establish the platform as an integrated component of the AI-driven diagnostic ecosystem. The company holds exclusive rights to a patented computer-aided diagnosis (CADx) module specifically designed for breast CT, enabling the potential for IzoView to deliver not only high-resolution images but also intelligent diagnostic support and automated triage capabilities.

As healthcare increasingly embraces AI analytics, cloud connectivity, and data interoperability, imaging systems that can seamlessly connect to analytical tools and clinical workflows are gaining importance. In this context, IzoView's ability to produce high-quality 3D volumetric datasets positions it as a valuable partner for AI developers and radiology groups seeking advanced platforms that support both image acquisition and data-driven interpretation.

Because IzoView captures true three-dimensional volumetric data rather than standard 2D images, it generates richer datasets with enhanced spatial resolution and quantitative volumetric details. This depth of data improves AI training potential, allowing for more precise modeling of breast tissue characteristics and early disease markers.

Over time, Izotropic could leverage this capability to form strategic collaborations, licensing agreements, or AI integration partnerships, expanding IzoView's value proposition from a stand-alone device to a gateway for next-generation clinical decision support tools built on its imaging architecture.

The market landscape surrounding Izotropic Corporation is both substantial and accelerating. Industry analysts forecast that the global breast imaging sector will expand at a compound annual growth rate (CAGR) of roughly 8.6% between 2023 and 2030, reaching about $9 billion by 2030. Similar projections place the market at $5.21 billion in 2024, growing to $10.37 billion by 2032, with a similar CAGR of 8.97%—underscoring steady momentum and sustained demand for next-generation imaging technologies.

Regional analyses indicate that North America will continue to lead global adoption, shaping both reimbursement practices and clinical implementation trends. Within this broader landscape, Izotropic highlights the digital breast tomosynthesis (DBT) market, projected to increase from $950 million in 2024 to $1.71 billion by 2030, reflecting a CAGR of approximately 10.28%.

On the regulatory front, Izotropic is executing a modular premarket approval (PMA) strategy in coordination with the U.S. Food and Drug Administration (FDA), allowing for staged data submissions as part of its path toward commercialization. The company has also outlined milestone-based roadmaps detailing its progression toward market entry.

With its proprietary AI reconstruction technology, potential integration of computer-aided diagnosis (CADx), and scalable commercialization framework, Izotropic is strategically positioned to compete in an expanding, innovation-driven imaging market—provided it successfully delivers on clinical validation, regulatory milestones, and market adoption.

The medical imaging sector is experiencing a period of rapid advancement as leading organizations invest in new technologies, strategic initiatives and innovative solutions. Across the industry, companies are expanding capabilities, integrating advanced imaging modalities and leveraging artificial intelligence to improve diagnostic accuracy, workflow efficiency and patient outcomes. These efforts reflect a broader trend of modernization and growth, highlighting the sector's increasing importance in healthcare and research.

NVIDIA Corp. has announced a collaboration with GE HealthCare to advance innovation in autonomous imaging, focused on developing autonomous X-ray technologies and ultrasound applications. According to the announcement, GE HealthCare is using the new NVIDIA Isaac(TM) for Healthcare medical device simulation platform, which includes pretrained models and physics-based simulations of sensors, anatomy and environments. The platform accelerates research and development workflows, enabling GE HealthCare to train, test and validate autonomous imaging system capabilities in a virtual environment before deployment in the physical world.

Butterfly Network Inc. has been included in the first edition of the World's Top HealthTech Companies 2025, presented by TIME and Statista Inc. The World's Top HealthTech Companies 2025 ranking recognizes leading innovators advancing healthcare globally through technology. Powered by its Ultrasound-on-Chip(TM) technology, Butterfly has reimagined traditional systems into a single, whole-body handheld probe. The latest award-winning iQ3 device delivers enhanced AI-powered features and sharp image capture, empowering healthcare workers to bring advanced diagnostic imaging directly to the point of care.

Lantheus Holdings Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for a new formulation of Lantheus's F 18 PSMA imaging agent filed by its affiliate, Aphelion. The FDA has set an action date goal of March 6, 2026, under the Prescription Drug User Fee Act (PDUFA). This NDA acceptance builds on the success of Lantheus' market-leading PSMA PET imaging agent, PYLARIFY, which has demonstrated high diagnostic performance and meaningful impact on clinical decision making.

Radnet Inc. and its wholly owned subsidiary, DeepHealth Inc., have received FDA 510(k) clearance for TechLive(TM), a remote scanning solution enabling centralized operation and supervision of MR, CT, PET/CT and ultrasound procedures. Amid tech labor shortages and inflationary wage pressure, TechLive empowers technologists to scan for multiple locations, enables improved operational efficiency, extends center operating hours and enhances access to complex procedures. More than 300 of RadNet's MR, CT, PET/CT and ultrasound systems are now connected with DeepHealth's TechLive solution, resulting in increased patient throughput and improved quality through remotely matching expert staff with complex modalities in real-time.

Recent developments underscore the ongoing transformation within medical imaging, as industry leaders continue to push boundaries in technology and operational excellence. Strategic advancements in imaging, AI integration, and workflow optimization demonstrate the sector's potential and illustrate a dynamic industry poised for continued innovation and long-term impact.

About NetworkNewsWire

NetworkNewsWire ("NNW") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness.

NNW is where breaking news, insightful content and actionable information converge.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

NetworkNewsWire is powered by IBN

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

NetworkNewsWire

New York, NY

www.NetworkNewsWire.com

212.418.1217 Office

[email protected]

Logo - https://mma.prnewswire.com/media/2660018/5578218/NetworkNewsWire_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/investors-turn-to-ai-driven-imaging-firms-targeting-high-growth-breast-cancer-market-302592056.html

SOURCE NetworkNewsWire